Literature DB >> 4790561

Effect of isoprinosine against influenza and some other viruses causing respiratory diseases.

R L Muldoon, L Mezny, G G Jackson.   

Abstract

The antiviral activity of isoprinosine was tested in tissue cultures and mice. In tissue cultures, concentrations of 25 to 100 mug/ml inhibited the infectivity of influenza and herpes hominis viruses but not parainfluenza virus, rhinovirus, or adenovirus. Among different strains of influenza A, there was considerable variability in the inhibitory concentration of isoprinosine. For influenza B, a zone effect was observed in the inhibitory drug concentration. Oral prophylactic administration of isoprinosine beginning 24 hr before infection with an intermediate challenge dose of influenza A and continued as treatment for 5 days produced a significant reduction in mortality. No protection was provided against a high dose challenge. Oral or intraperitoneal treatment of mice beginning 24 hr after infection with influenza A or B viruses significantly delayed or prevented death when the drug was administered for 10 days, but not when treatment was limited to 4 days. An increased fatality rate which occurred in treated mice given a virus dose of low lethality could not be attributed to drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4790561      PMCID: PMC444295          DOI: 10.1128/AAC.2.3.224

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  1 in total

Review 1.  Molecular approaches to the drug enhancement of deteriorated functioning in the aged.

Authors:  P Gordon
Journal:  Adv Gerontol Res       Date:  1971
  1 in total
  10 in total

1.  Evaluation of isoprinosine in experimental human rhinovirus infection.

Authors:  D M Pachuta; Y Togo; R B Hornick; A R Schwartz; S Tominaga
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

2.  Protective effect of isoprinosine in genetically susceptible BALB/c mice infected with Leishmania major.

Authors:  E Cillari; M Dieli; P Lo Campo; G Sireci; A Caffarelli; E Maltese; S Millott; S Milano; F Y Liew
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

Review 3.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

4.  Isoprinosine in classical acute viral hepatitis.

Authors:  K C Lam; H J Lin; C L Lai; S K Lam; Y L Kwan
Journal:  Am J Dig Dis       Date:  1978-10

5.  Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers.

Authors:  A J Soto; T S Hall; S E Reed
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

6.  Anti-herpesvirus action of isoprinosine.

Authors:  P Gordon; B Ronsen; E R Brown
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

7.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

8.  Effect of isoprinosine against challenge with A(H3N2)-Hong Kong influenza virus in volunteers.

Authors:  S Longley; R L Dunning; R H Waldman
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

Review 9.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 10.  Battling COVID-19: using old weapons for a new enemy.

Authors:  Rohit Kumar; Nitin Gupta; Parul Kodan; Ankit Mittal; Manish Soneja; Naveet Wig
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.